Algorithm
- Company typePrivate
- Founded1961
- HeadquartersBeirut, Lebanon
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Algorithm does
Algorithm SAL is a privately held Lebanese regional pharmaceutical company founded in 1961 (originally as Charles E. Frosst & Co. (M.E.) SAL, a subsidiary of Merck & Co. Inc.) and acquired by Droguerie De L'Union shareholders in December 1989. The company manufactures and commercializes pharmaceutical products across the MENA region, combining in-house differentiated generics (e.g., Ziorel, Ziorel Plus, Zevlen) with licensed products from international originators including Merck, Recordati, Organon, Teijin, Kowa, Advanz, Curax, and Biogen. Its therapeutic portfolio spans seven areas: antithrombotic therapy, central nervous system, diabetes, dyslipidemia, hypertension, obesity, and primary care, with more than 100 products in market.
The company operates two GMP-certified manufacturing facilities in Lebanon — a primary site in Zouk Mosbeh and an expanded, LEED Gold-certified plant in Zekrit — supported by Medical Affairs, Regulatory Affairs, Marketing, and Market Access functions. Algorithm distributes through a direct field sales force targeting physicians, pharmacists, and hospital procurement teams across 9+ MENA countries (Lebanon, Saudi Arabia, Kuwait, UAE, Jordan, Egypt, Iraq, and others), supplemented by channel partners such as Batterjee Pharma for Saudi localization and Bejaa Scientific Office for Iraq. In September 2025 it signed a landmark localization agreement with Batterjee Pharma, targeting full technology transfer by mid-2026 and becoming the first Lebanese company to lead portfolio localization in Saudi Arabia under Vision 2030.
Algorithm generates revenue through the manufacture, promotion, and distribution of branded pharmaceutical products via one-time license arrangements with multinational partners and direct sales of differentiated generics. Its go-to-market is enterprise field sales reinforced by medical congress participation, scientific symposia, continuing medical education, and site visits to its manufacturing facilities. The company is TRACE certified since 2019 and operates an FCPA-aligned compliance program, which underpins its standing as a trusted regional partner for multinational licensors.
Algorithm firmographics
Firmographics- Name
- Algorithm
- Legal name
- Algorithm SAL
- Website
- https://algorithm-lb.com
- Company type
- Private
- Founded year
- 1961
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Algorithm industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Algorithm is headquartered
LocationHeadquarters
- HQ city
- Beirut
- HQ country
- Lebanon
- HQ region
- Middle East
Offices3 records
Markets served
Algorithm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- Pharmaceutical product sales: Algorithm generates revenue through the manufacture, promotion, and distribution of branded pharmaceutical products. Revenue comes from licensed products sourced from international pharmaceutical partners and differentiated in-house generic products sold across MENA markets through direct sales channels and regional distributors.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Algorithm product offering
Product offeringCore offering
Algorithm manufactures and commercializes branded pharmaceutical products under license from international companies (Merck, Recordati, Organon, Teijin, Kowa, Advanz, Curax) and differentiated in-house generics across seven therapeutic areas: Antithrombotic Therapy, Central Nervous System, Diabetes, Dyslipidemia, Hypertension, Obesity, and Primary Care. The company operates two GMP-certified manufacturing facilities in Lebanon and distributes its 100+ products through a regional field sales force and strategic distribution partnerships across 9+ MENA countries.
Product overview
Algorithm is a regional pharmaceutical company operating across the MENA region, committed to improving human health and well-being. The company manufactures and commercializes innovative pharmaceutical products both under license from international companies and as differentiated generics. Its therapeutic portfolio focuses on seven key therapeutic areas: Antithrombotic Therapy (including Aggrastat), Central Nervous System, Diabetes, Dyslipidemia (including Livazo), Hypertension (including Ziorel and Ziorel Plus), Obesity, and Primary Care (including cold/flu products, antibiotics like Zevlen, and gastro products like Exonar). The company operates two manufacturing facilities in Lebanon (Zouk and Zekrit) and distributes products across 9+ countries in the MENA region. Beyond its product portfolio, Algorithm provides access channels including Medical Affairs, Regulatory Affairs, Marketing, and Market Access services.
Differentiator
Problem solved
Functional benefit
Brands
- Livazo: Featured product for Dyslipidemia
- 123 Complete Cold, Cough and Flu
- Adenuric
- Aggrastat
- Exonar
Products and services
- Livazo
- Aggrastat
- Adenuric
- Zevlen
- Ziorel
- Ziorel Plus
- Exonar
- 123 Complete Cold, Cough and Flu
- 123 Cold & Flu
Quantifiable outcome
- Over 100 high-quality pharmaceutical products manufactured and distributed across MENA
- +2 more outcomes
Companies that use Algorithm
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Algorithm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Algorithm partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Batterjee PharmacoreAlgorithm and Batterjee Pharma signed a landmark strategic partnership agreement for local manufacturing of Algorithm's pharmaceutical products in the Kingdom of Saudi Arabia. The collaboration covers differentiated products targeting hyperlipidemia, dyslipidemia, hypertension, chronic weight management, and acute coronary syndrome, with full technology transfer expected by mid-2026. This aligns with Saudi Vision 2030's Health Sector Transformation Program.
- Bejaa Scientific OfficecoreStrategic partnership for registration, commercialization, and distribution of Algorithm's pharmaceutical products in Iraq. Unveiled at a high-profile event under the patronage of the Iraqi Minister of Health, represented by Pr. Salih Al-Hasnawi, with key stakeholders from the Iraqi healthcare ecosystem.
- Recordati IrelandcoreRecordati Ireland visits to Algorithm's Zekrit manufacturing facility. The partnership dates back to 1997; Algorithm is responsible for manufacturing, promotion, and distribution of Recordati products within cardiac and primary care therapeutic areas in the Levant and Gulf region.
- Lebanese American University (LAU) School of PharmacyminorAlgorithm partners with LAU School of Pharmacy for the 5th consecutive year providing one-month industrial rotation for Doctor of Pharmacy (Pharm.D.) students. Algorithm engages its technical and commercial departments to provide practical insights including field experience.
- Biogencore20 years of partnership between Biologix and Biogen. Senior leadership from Biogen visited Algorithm facilities to celebrate the milestone, reflecting on successes and challenges and emphasizing commitment to serving patients in the Middle East.
- RecordaticoreLong-term strategic licensing and co-development partnership for cardiac and primary care products. Algorithm manufactures, promotes, and distributes Recordati products across the Levant and Gulf region.
- MerckcoreHistorical licensing partnership. Algorithm originated as Charles E. Frosst & Co. (M.E.) SAL, a subsidiary of Merck & Co. Inc. (MSD), before acquisition in December 1989.
- OrganoncoreStrategic partnership for pharmaceutical products promoted and distributed by Algorithm in MENA markets under license from Organon.
- TeijincoreLicensing partnership for pharmaceutical products distributed by Algorithm across MENA markets under license from Teijin.
- KowacoreLicensing partnership for pharmaceutical products distributed by Algorithm across MENA markets under license from Kowa.
- AdvanzcoreLicensing partnership for pharmaceutical products distributed by Algorithm across MENA markets under license from Advanz.
- CuraxcoreLicensing partnership for pharmaceutical products distributed by Algorithm across MENA markets under license from Curax.
- Biologix FZCocoreBiologix specializes in bringing innovative drugs from multinational manufacturers to the MENA market through its network of over 17 strategic locations. Biologix is part of the Algorithm group operating alongside Algorithm Pharmaceutical Manufacturers, covering both licensed products and differentiated generics.
Scale indicators5 records
Recent moves9 records
Expansion highlights6 records
Algorithm competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Algorithm social profiles
Digital presenceAlgorithm compliance and trust
Trust signalCompliance3 records
Algorithm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Algorithm leadership team
Management profileNumber of profiles
Profiles10 records
Algorithm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Algorithm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Algorithm
What does Algorithm do?
Algorithm manufactures and commercializes branded pharmaceutical products under license from international companies (Merck, Recordati, Organon, Teijin, Kowa, Advanz, Curax) and differentiated in-house generics across seven therapeutic areas: Antithrombotic Therapy, Central Nervous System, Diabetes, Dyslipidemia, Hypertension, Obesity, and Primary Care. The company operates two GMP-certified manufacturing facilities in Lebanon and distributes its 100+ products through a regional field sales force and strategic distribution partnerships across 9+ MENA countries.
Is Algorithm a public or private company?
Algorithm is a private company. It is classified as family owned and is currently operating.
When was Algorithm founded?
Algorithm was founded in 1961. It employs 251 to 500 people.
Where is Algorithm based?
Algorithm is headquartered in Beirut, Lebanon, in the Middle East region.
How does Algorithm make money?
One revenue line is on record: pharmaceutical product sales.
Does Algorithm have an API?
No public API is recorded for Algorithm.
What industry is Algorithm in?
Algorithm's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 32541 and its SIC code is 2834.